Leading Independent Proxy Advisory Firms Recommend Conatus Pharmaceuticals Shareholders Vote in Favor of its Merger with Histogen and the Required Reverse Stock Split
May 18, 2020 08:00 ET
|
Conatus Pharmaceuticals Inc.
SAN DIEGO, May 18, 2020 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced that Institutional Shareholder Services Inc. (ISS) and Glass Lewis, two leading independent...
Histogen Publishes Preclinical Data on its HST 004 Spinal Disc Program
May 14, 2020 08:00 ET
|
Conatus Pharmaceuticals Inc.; Histogen Inc.
SAN DIEGO, May 14, 2020 (GLOBE NEWSWIRE) -- Histogen Inc., a regenerative medicine company with a novel biological platform that replaces and regenerates tissues in the body, announced today the...
Histogen Receives US FDA IND Approval to Initiate Phase 1b/2a Trial of HST 001 in Androgenic Alopecia
May 11, 2020 08:00 ET
|
Conatus Pharmaceuticals Inc.; Histogen Inc.
SAN DIEGO, May 11, 2020 (GLOBE NEWSWIRE) -- Histogen Inc., a regenerative medicine company with a novel biological platform that replaces and regenerates tissues in the body, announced today that...
The Conatus Pharmaceuticals Special Meeting of Stockholders Seeking Approval for Proposed Merger with Histogen Inc. will Reconvene on May 21, 2020
May 07, 2020 16:05 ET
|
Conatus Pharmaceuticals Inc.
SAN DIEGO, May 07, 2020 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today convened and adjourned its special meeting of stockholders in order to obtain a quorum and specific...
Conatus Pharmaceuticals Reports First Quarter 2020 Financial Results and Strategic Process Update
May 01, 2020 16:05 ET
|
Conatus Pharmaceuticals Inc.
SAN DIEGO, May 01, 2020 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced financial results for the first quarter ended March 31, 2020 and provided an update on its...
Histogen Announces Investigational Device Exemption Application for HST 002
April 20, 2020 08:00 ET
|
Conatus Pharmaceuticals Inc.
SAN DIEGO, April 20, 2020 (GLOBE NEWSWIRE) -- Histogen Inc., a regenerative medicine company with a novel biological platform that replaces and regenerates tissues in the body, announced today that...
Histogen Publishes New Preclinical Data on its HST 003 Orthopedic Program
April 15, 2020 08:00 ET
|
Conatus Pharmaceuticals Inc.; Histogen Inc.
SAN DIEGO, April 15, 2020 (GLOBE NEWSWIRE) -- Histogen Inc., a regenerative medicine company with a novel biological platform that replaces and regenerates tissues in the body, announced today the...
Histogen Announces Investigational New Drug Application Amendment for HST 001
April 06, 2020 08:00 ET
|
Conatus Pharmaceuticals Inc.; Histogen Inc.
SAN DIEGO, April 06, 2020 (GLOBE NEWSWIRE) -- Histogen Inc., a regenerative medicine company with a novel biological platform that replaces and regenerates tissues in the body, announced today that...
Conatus Pharmaceuticals Reports 2019 Financial Results and Strategic Process Update
March 11, 2020 16:45 ET
|
Conatus Pharmaceuticals Inc.
SAN DIEGO, March 11, 2020 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced financial results for the fourth quarter and full year ended December 31, 2019, and provided...
Conatus Pharmaceuticals and Histogen Enter into Definitive Merger Agreement
January 28, 2020 16:05 ET
|
Conatus Pharmaceuticals Inc.
Proposed Merger Creates Regenerative Medicine Company with Three Clinical-stage Product Candidates and Combined Company Capitalization Expected to Support Operations into 2021 Companies to Hold a...